JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages.
JAK2 genetic variants are associated with inflammatory bowel disease (IBD) and JAK inhibitors are being evaluated for therapy targeting immune-mediated diseases, including IBD. As JAK pathway-mediated cytokine regulation varies across cell types and stimulation conditions, we examined how JAK signaling and IBD-associated JAK2 variants regulate distinct acute and chronic microbial product exposure outcomes in human myeloid cells, consistent with the conditions of initial entry and ongoing intestinal tissue residence, respectively. Macrophages from controls and ulcerative colitis patients carrying the IBD-risk rs10758669 CC genotype showed increased JAK2 expression and nucleotide-binding oligomerization domain 2-induced JAK2 phosphorylation relative to AA carriers. Interestingly, the threshold of JAK2 expression and signaling determined pattern-recognition receptor (PRR)-induced outcomes; whereas anti-inflammatory cytokines progressively decreased with lower JAK2 expression, proinflammatory cytokines switched from decreased to increased secretion below a certain JAK2 expression threshold. Low JAK2-expressing rs10758669 AA macrophages were above this threshold; consequently, both PRR-induced pro- and anti-inflammatory cytokines were decreased. However, relative to rs10758669 CC risk carriers, AA carrier macrophages switched to increased nucleotide-binding oligomerization domain 2-induced proinflammatory cytokines at lower therapeutically used JAK inhibitor doses. Importantly, JAK inhibitors increased proinflammatory cytokines secreted by peripheral macrophages following chronic PRR stimulation and by human intestinal myeloid cells following exposure to intestinal pathogens. Mechanistically, the decreased response to and secretion of autocrine/paracrine IL-10, IL-4, IL-22 and thymic stromal lymphopoietin regulated these JAK-dependent outcomes in myeloid cells. Taken together, the JAK signaling threshold determines whether PRR-induced pro- and anti-inflammatory cytokines are reciprocally regulated in myeloid cells; consideration of JAK2 genotype and targeting of specific cell types might improve JAK-targeted therapy in immune-mediated diseases.
Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT 06520.
Matija
M
Hedl
Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT 06520.
Deborah D
DD
Proctor
Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT 06520 clara.abraham@yale.edu.
Clara
C
Abraham
D000328:Adult; D000483:Alleles; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005838:Genotype; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000235:genetics / Q000276:immunology*; D053614:Janus Kinase 2 / Q000235:genetics / Q000378:metabolism*; D008264:Macrophages / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction; D016896:Treatment Outcome
D016207:Cytokines; D018836:Inflammation Mediators; D047428:Protein Kinase Inhibitors; C507924:JAK2 protein, human; D053614:Janus Kinase 2
Immunity. 2011 May 27;34(5):769-80
21565531
J Biol Chem. 2015 Dec 4;290(49):29301-12
26451047
Nat Immunol. 2014 Oct;15(10):929-937
25151491
N Engl J Med. 2010 Sep 16;363(12):1117-27
20843246
J Exp Med. 2012 Jan 16;209(1):139-55
22231304
J Biol Chem. 2013 Nov 1;288(44):31795-806
24045942
Nat Rev Immunol. 2014 May;14(5):329-42
24751956
Gastroenterology. 2011 Jan;140(1):231-41
20854823
J Immunol. 2010 Jun 15;184(12):6843-54
20483766
Nat Rev Immunol. 2014 Dec;14(12):783-95
25421700
Gastroenterology. 2012 Dec;143(6):1530-43
22967725
Gastroenterology. 2011 May;140(6):1729-37
21530739
Immunity. 2012 Apr 20;36(4):542-50
22520847
Clin Gastroenterol Hepatol. 2014 Sep;12(9):1485-93.e2
24480677
Nat Immunol. 2012 May;13(5):449-56
22484733
N Engl J Med. 2012 Aug 16;367(7):616-24
22894574
Drug Metab Dispos. 2014 Apr;42(4):759-73
24464803
Nat Immunol. 2010 Apr;11(4):289-93
20300138
J Exp Med. 2013 Mar 11;210(3):517-34
23460728
J Clin Invest. 2008 Feb;118(2):545-59
18188453
J Immunol. 2014 Apr 1;192(7):3409-18
24591373
J Clin Pharmacol. 2014 Jan;54(1):46-52
24030917
Lancet. 1999 Feb 27;353(9154):717-9
10073515
Nat Genet. 2008 Aug;40(8):955-62
18587394
N Engl J Med. 2009 Nov 19;361(21):2066-78
19923578
J Immunol. 2013 Aug 1;191(3):1164-74
23797672
J Immunol. 2006 Nov 15;177(10):7303-11
17082649
Blood. 2001 Jul 1;98(1):231-4
11418485
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19440-5
18032608
J Immunol. 2012 Sep 15;189(6):2784-92
22904308
Int J Colorectal Dis. 2012 May;27(5):565-73
22065112
J Immunol. 2011 Apr 1;186(7):4234-43
21383241
Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii111-5
23532440
Arthritis Rheum. 2012 Dec;64(12):3856-66
22941906
Mol Cell Biol. 2013 Dec;33(24):4857-71
24100018
J Clin Invest. 2005 Jan;115(1):66-75
15630445
Blood Cancer J. 2011 Dec;1(12):e46
22829094
Gastroenterology. 2014 Oct;147(4):835-46
24960189
J Immunol. 2012 Jan 15;188(2):864-73
22156348